Inhibition of p38 MAPK attenuates renal atrophy and fibrosis in a murine renal artery stenosis model

American Journal of Physiology - Renal Physiology

Volumn 304, Issue 7, 2013, Pages

  Wang, Diping ^a   Warner, Gina M ^a   Yin, Ping ^a   Knudsen, Bruce E ^a   Cheng, Jingfei ^a   Butters, Kim A ^a   Lien, Karen R ^a   Gray, Catherine E ^a   Garovic, Vesna D ^a   Lerman, Lilach O ^a   Textor, Stephen C ^a   Nath, Karl A ^a   Simari, Robert D ^a   Grande, Joseph P ^a  

^a MAYO CLINIC   (United States)

Author keywords

Atrophy; CCL2; CCR2; Fibrosis; Renal artery stenosis

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CHEMOKINE RECEPTOR CCR2; COLLAGEN TYPE 4; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; CCL2 PROTEIN, MOUSE; CCL7 PROTEIN, MOUSE; CCR2 PROTEIN, MOUSE; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; CONTROLLED STUDY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HYPERTENSION; IN VITRO STUDY; KIDNEY ARTERY STENOSIS; KIDNEY ATROPHY; KIDNEY DISEASE; KIDNEY FIBROSIS; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FIBROSIS; KIDNEY; METABOLISM; NEPHROSCLEROSIS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ATROPHY; CHEMOKINE CCL2; CHEMOKINE CCL7; DISEASE MODELS, ANIMAL; FIBROSIS; IMIDAZOLES; KIDNEY; MALE; MICE; MICE, INBRED C57BL; NEPHROSCLEROSIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RECEPTORS, CCR2; RENAL ARTERY OBSTRUCTION; SIGNAL TRANSDUCTION; UP-REGULATION;

MLCS; MLOWN;

EID: 84878259744     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00706.2012     Document Type: Article

References (51)

1. Bao W, Behm DJ, Nerurkar SS, Ao Z, Bentley R, Mirabile RC, Johns DG, Woods TN, Doe CP, Coatney RW, Ohlstein JF, Douglas SA, Willette RN, Yue TL. Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production. J Cardiovasc Pharmacol 49: 362-368, 2007.
2. Bian ZM, Elner SG, Yoshida A, Kunkel SL, Su J, Elner VM. Activation of p38, ERK1/2 and NIK pathways is required for IL-1fj and TNF-a-induced chemokine expression in human retinal pigment epithelial cells. Exp Eye Res 73: 111-121, 2001.
3. Brook M, Tchen CR, Santalucia T, McIlrath J, Arthur JS, Saklatvala J, Clark AR. Posttranslational regulation of tristetraprolin subcellular localization and protein stability by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase pathways. Mol Cell Biol 26: 2408-2418, 2006.
4. Carrick DM, Lai WS, Blackshear PJ. The tandem CCCH zinc finger protein tristetraprolin and its relevance to cytokine mRNA turnover and arthritis. Arthritis Res Ther 6: 248-264, 2004.
5. Cheng J, Diaz Encarnacion MM, Warner GM, Gray CE, Nath KA, Grande JP. TGF-fj1 stimulates monocyte chemoattractant protein-1 expression in mesangial cells through a phosphodiesterase isoenzyme 4-de-pendent process. Am J Physiol Cell Physiol 289: C959-C970, 2005.
6. Cheng J, Zhou W, Warner GM, Knudsen BE, Garovic VD, Gray CE, Lerman LO, Platt JL, Romero JC, Textor SC, Nath KA, Grande JP. Temporal analysis of signaling pathways activated in a murine model of 2-kidney, 1-clip hypertension. Am J Physiol Renal Physiol 297: F1055-F1068, 2009.
7. Cuenda A, Rousseau S. P38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773: 1358-1375, 2007.
8. de Borst MH, Navis G, de Boer RA, Huitema S, Vis LM, van Gilst WH, van Goor H. Specific MAP-kinase blockade protects against renal damage in homozygous TGR(mRen2)27 rats. Lab Invest 83: 1761-1770, 2003.
9. Diaz Encarnacion MM, Griffin MD, Slezak JM, Bergstralh EJ, Stegall MD, Velosa JA, Grande JP. Correlation of quantitative digital image analysis with the glomerular filtration rate in chronic allograft nephropathy. Am J Transplant 4: 248-256, 2004.
10. Diaz Encarnacion MM, Warner GM, Cheng J, Gray CE, Nath KA, Grande JP. n-3 Fatty acids block TNF-a-stimulated MCP-1 expression in rat mesangial cells. Am J Physiol Renal Physiol 300: F1142-F1151, 2011.
11. Ebrahimian T, Li MW, Lemarie CA, Simeone SM, Pagano PJ, Gaestel M, Paradis P, Wassmann S, Schiffrin EL. Mitogen-activated protein kinase-activated protein kinase 2 in angiotensin II-induced inflammation and hypertension: regulation of oxidative stress. Hypertension 57: 245-254, 2011.
12. Feng M, Whitesall S, Zhang Y, Beibel M, D'Alecy L, DiPetrillo K. Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertens 21: 1288-1291, 2008.
13. Giunti S, Pinach S, Arnaldi L, Viberti G, Perin PC, Camussi G, Gruden G. The MCP-1/CCR2 system has direct proinflammatory effects in human mesangial cells. Kidney Int 69: 856-863, 2006.
14. Gordon JR. TGF-fj1 and TNF-a secreted by mast cells stimulated via the FcepsilonRI activate fibroblasts for high-level production of monocyte chemoattractant protein-1 (MCP-1). Cell Immunol 201: 42-49, 2000.
15. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 346: 1954-1962, 2002.
16. Hogaboam CM, Bone-Larson CL, Lipinski S, Lukacs NW, Chensue SW, Strieter RM, Kunkel SL. Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1- and Th2-type pulmonary granuloma models. J Immunol 163: 2193-2201, 1999.
17. Ivanenkov YA, Balakin KV, Tkachenko SE. New approaches to the treatment of inflammatory disease: focus on small-molecule inhibitors of signal transduction pathways. Drugs R D 9: 397-434, 2008.
18. Jin N, Wang Q, Zhang X, Jiang D, Cheng H, Zhu K. The selective p38 mitogen-activated protein kinase inhibitor, SB203580, improves renal disease in MRL/lpr mouse model of systemic lupus. Int Immunopharma-col 11: 1319-1326, 2011.
19. Kawano H, Kim S, Ohta K, Nakao T, Miyazaki H, Nakatani T, Iwao H. Differential contribution of three mitogen-activated protein kinases to PDGF-BB-induced mesangial cell proliferation and gene expression. J Am Soc Nephrol 14: 584-592, 2003.
20. Kitagawa K, Wada T, Furuichi K, Hashimoto H, Ishiwata Y, Asano M, Takeya M, Kuziel WA, Matsushima K, Mukaida N, Yokoyama H. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 165: 237-246, 2004.
21. Lloyd CM, Minto AW, Dorf ME, Proudfoot A, Wells TN, Salant DJ, Gutierrez-Ramos JC. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis J Exp Med 185: 1371-1380, 1997.
22. Ma FY, Liu J, Nikolic-Paterson DJ. The role of stress-activated protein kinase signaling in renal pathophysiology. Braz J Med Biol Res 42: 29-37, 2009.
23. Ma JY, Medicherla S, Kerr I, Mangadu R, Protter AA, Higgins LS. Selective p38a mitogen-activated protein kinase inhibitor attenuates lung inflammation and fibrosis in IL-13 transgenic mouse model of asthma. J Asthma 1: 31-44, 2008.
24. Matoba K, Kawanami D, Ishizawa S, Kanazawa Y, Yokota T, Ut-sunomiya K. Rho-kinase mediates TNF-a-induced MCP-1 expression via p38 MAPK signaling pathway in mesangial cells. Biochem Biophys Res Commun 402: 725-730, 2010.
25. Meng XM, Huang XR, Xiao J, Chung AC, Qin W, Chen HY, Lan HY. Disruption of Smad4 impairs TGF-fj/Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro. Kidney Int 81: 266-279, 2012.
26. Minuz P, Patrignani P, Gaino S, Degan M, Menapace L, Tommasoli R, Seta F, Capone ML, Tacconelli S, Palatresi S, Bencini C, Del Vecchio C, Mansueto G, Arosio E, Santonastaso CL, Lechi A, Mor-ganti A, Patrono C. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 106: 2800-2805, 2002.
27. Moore BB, Paine R III, Christensen PJ, Moore TA, Sitterding S, Ngan R, Wilke CA, Kuziel WA, Toews GB. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol 167: 4368-4377, 2001.
28. Moran N. P38 kinase inhibitor approved for idiopathic pulmonary fibrosis. Nat Biotechnol 29: 301, 2011.
29. Munoz L, Ramsay EE, Manetsch M, Ge Q, Peifer C, Laufer S, Ammit AJ. Novel p38 MAPK inhibitor ML3403 has potent anti-inflammatory activity in airway smooth muscle. Eur J Pharmacol 635: 212-218, 2010.
30. Nishida M, Okumura Y, Sato H, Hamaoka K. Delayed inhibition of p38 mitogen-activated protein kinase ameliorates renal fibrosis in obstructive nephropathy. Nephrol Dial Transplant 23: 2520-2524, 2008.
31. Ohashi R, Nakagawa T, Watanabe S, Kanellis J, Almirez RG, Schreiner GF, Johnson RJ. Inhibition of p38 mitogen-activated protein kinase augments progression of remnant kidney model by activating the ERK pathway. Am J Pathol 164: 477-485, 2004.
32. Ong VH, Evans LA, Shiwen X, Fisher IB, Rajkumar V, Abraham DJ, Black CM, Denton CP. Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum 48: 1979-1991, 2003.
33. Oto T, Calderone A, Li Z, Rosenfeldt FL, Pepe S. p38 Mitogen-activated protein kinase inhibition reduces inflammatory cytokines in a brain-dead transplant donor animal model. Heart Lung Circ 18: 393-400, 2009.
34. Park J, Ryu DR, Li JJ, Jung DS, Kwak SJ, Lee SH, Yoo TH, Han SH, Lee JE, Kim DK, Moon SJ, Kim K, Han DS, Kang SW. MCP-1/CCR2 system is involved in high glucose-induced fibronectin and type IV collagen expression in cultured mesangial cells. Am J Physiol Renal Physiol 295: F749-F757, 2008.
35. Park JK, Fischer R, Dechend R, Shagdarsuren E, Gapeljuk A, Well-ner M, Meiners S, Gratze P, Al-Saadi N, Feldt S, Fiebeler A, Madwed JB, Schirdewan A, Haller H, Luft FC, Muller DN. P38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage. Hypertension 49: 481-489, 2007.
36. Pettus LH, Wurz RP. Small molecule p38 MAP kinase inhibitors for the treatment of inflammatory diseases: novel structures and developments during 2006-2008. Curr Top Med Chem 8: 1452-1467, 2008.
37. Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 344: 431-442, 2001.
38. Schieven GL. The p38a kinase plays a central role in inflammation. Curr Top Med Chem 9: 1038-1048, 2009.
39. Schindler JF, Monahan JB, Smith WG. P38 pathway kinases as antiinflammatory drug targets. J Dental Res 86: 800-811, 2007.
40. Schwarz M, Wahl M, Resch K, Radeke HH. IFN--/ induces functional chemokine receptor expression in human mesangial cells. Clin Exp Immunol 128: 285-294, 2002.
41. Stahl RA, Thaiss F, Disser M, Helmchen U, Hora K, Schlondorff D. Increased expression of monocyte chemoattractant protein-1 in anti- thymocyte antibody-induced glomerulonephritis. Kidney Int 44: 1036-1047, 1993.
42. Stambe C, Atkins RC, Tesch GH, Masaki T, Schreiner GF, Nikolic-Paterson DJ. The role of p38a mitogen-activated protein kinase activation in renal fibrosis. J Am Soc Nephrol 15: 370-379, 2004.
43. Stambe C, Nikolic-Paterson DJ, Hill PA, Dowling J, Atkins RC. P38 Mitogen-activated protein kinase activation and cell localization in human glomerulonephritis: correlation with renal injury. J Am Soc Nephrol 15: 326-336, 2004.
44. Viedt C, Vogel J, Athanasiou T, Shen W, Orth SR, Kubler W, Kreuzer J. Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-KB and activator protein-1. Arterioscler Thromb Vasc Biol 22: 914-920, 2002.
45. Wada T, Furuichi K, Sakai N, Hisada Y, Kobayashi K, Mukaida N, Tomosugi N, Matsushima K, Yokoyama H. Involvement of p38 mitogen-activated protein kinase followed by chemokine expression in cres-centic glomerulonephritis. Am J Kidney Dis 38: 1169-1177, 2001.
46. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, Takeda SI, Takasawa K, Yoshimura M, Kida H, Kobayashi KI, Mukaida N, Naito T, Matsushima K, Yokoyama H. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 58: 1492-1499, 2000.
47. Warner GM, Cheng J, Knudsen BE, Gray CE, Deibel A, Juskewitch JE, Lerman LO, Textor SC, Nath KA, Grande JP. Genetic deficiency of Smad3 protects the kidneys from atrophy and interstitial fibrosis in 2K1C hypertension. Am J Physiol Renal Physiol 302: F1455-F1464, 2012.
48. Weber KS, Nelson PJ, Grone HJ, Weber C. Expression of CCR2 by endothelial cells: implications for MCP-1 mediated wound injury repair and In vivo inflammatory activation of endothelium. Arterioscler Thromb Vasc Biol 19: 2085-2093, 1999.
49. Yong HY, Koh MS, Moon A. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investig Drugs 18: 1893-1905, 2009.
50. Zhu XY, Daghini E, Chade AR, Napoli C, Ritman EL, Lerman A, Lerman LO. Simvastatin prevents coronary microvascular remodeling in renovascular hypertensive pigs. J Am Soc Nephrol 18: 1209-1217, 2007.
51. Zhu Z, Ma B, Zheng T, Homer RJ, Lee CG, Charo IF, Noble P, Elias JA. IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 168: 2953-2962, 2002.